Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia.

Drake RE, Xie H, McHugo GJ, Green AI.

Schizophr Bull. 2000;26(2):441-9.

PMID:
10885642
2.
3.

Substance abuse in schizophrenia: a review.

Buckley PF.

J Clin Psychiatry. 1998;59 Suppl 3:26-30. Review.

4.

Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches.

Green AI.

J Clin Psychiatry. 2006;67 Suppl 7:31-5; quiz 36-7. Review.

5.

Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder.

Wagstaff A, Perry C.

CNS Drugs. 2003;17(4):273-80; discussion 281-3. Review.

PMID:
12665398
6.

Treatment of schizophrenia and comorbid substance use disorder.

Green AI, Salomon MS, Brenner MJ, Rawlins K.

Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):129-39. Review.

PMID:
12769622
7.

Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Noordsy DL, Green AI.

Curr Psychiatry Rep. 2003 Oct;5(5):340-6. Review.

PMID:
13678553
8.

Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders.

San L, Arranz B, Martinez-Raga J.

Eur Addict Res. 2007;13(4):230-43. Review.

PMID:
17851245
9.

Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Green AI.

Neurotox Res. 2007 Jan;11(1):33-40. Review.

PMID:
17449446
10.

[Leponex, 10 years after -- a clinical review].

Llorca PM, Pere JJ.

Encephale. 2004 Sep-Oct;30(5):474-91. Review. French.

PMID:
15627052
12.

Pharmacological treatment of schizophrenia and co-occurring substance use disorders.

Smelson DA, Dixon L, Craig T, Remolina S, Batki SL, Niv N, Owen R.

CNS Drugs. 2008;22(11):903-16. Review.

PMID:
18840032
13.

Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

Houthoofd SA, Morrens M, Sabbe BG.

Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Review.

PMID:
18840365
14.

Pharmacotherapy of schizophrenia with comorbid substance use disorder--reviewing the evidence and clinical recommendations.

Wobrock T, Soyka M.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1375-85. doi: 10.1016/j.pnpbp.2008.02.008. Epub 2008 Feb 26. Review.

PMID:
18394768
15.

The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.

Haro JM, Salvador-Carulla L.

CNS Drugs. 2006;20(4):293-301. Review.

PMID:
16599647
16.

[Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].

Wobrock T, D'Amelio R, Falkai P.

Nervenarzt. 2008 Jan;79(1):17-8, 20-2, 24-6 passim. Review. German.

PMID:
17619840
17.

Management of schizophrenia with substance use disorders.

Lybrand J, Caroff S.

Psychiatr Clin North Am. 2009 Dec;32(4):821-33. doi: 10.1016/j.psc.2009.09.002. Review.

PMID:
19944886
18.
19.

The expanding indications for clozapine.

Young CR, Longhurst JG, Bowers MB Jr, Mazure CM.

Exp Clin Psychopharmacol. 1997 Aug;5(3):216-34. Review.

PMID:
9260069
20.

Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.

Coyle JT.

Neurotox Res. 2006 Dec;10(3-4):221-33. Review.

PMID:
17197372

Supplemental Content

Support Center